Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "Pfizer"

177 News Found

Covid-19 vaccine clinical trial for people with autoimmune disease
Drug Approval | September 03, 2021

Covid-19 vaccine clinical trial for people with autoimmune disease

Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study


Brazil’s Eurofarma to manufacture Comirnaty for Latin America
Biotech | August 27, 2021

Brazil’s Eurofarma to manufacture Comirnaty for Latin America

The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually


Govt. to allow 100% doses of imported and ready to use foreign vaccine
News | May 14, 2021

Govt. to allow 100% doses of imported and ready to use foreign vaccine

Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India


Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.


Sputnik V needs to be priced at par with Covishield & Covaxin
News | April 23, 2021

Sputnik V needs to be priced at par with Covishield & Covaxin

Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply


Merck FY20 sales up 8.6% euro 17.5 bn
News | March 04, 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.


Pharma industry bullish on complex generics and biosimilars
News | February 25, 2021

Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side